Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”ASH25: Introducing fixed-dose marstacimab as prophylaxis for patients with haemophilia A and B with inhibitors (>12 years and < 75 years).
Phase 3 BASIS trial results presented by Davide Matino at ASH2025 demonstrate safety and efficay data.
Marstacimab, a monoclonal IgG1 antibody targeting tissue factor pathway inhibitor (TFPI), increased thrombin generation and clot formation. In the BASIS trial, weekly subcutaneous (SC) marstacimab at 150 mg (after 300 mg loading dose) proved superior to on-demand treatment:
- Primary endpoint exceeded: Marstacimab reduced annualized bleeding rate (ABR) for treated bleeds to 1.4 vs. 19.8 for on-demand (p<0.0001) — a 93% reduction
- Consistent efficacy across populations: ABR reductions held steady across hemophilia type (A and B), age groups (adolescents and adults), and geographic regions
- Meaningful clinical impact: 57.8% of marstacimab-treated patients achieved zero treated bleeds during follow-up
- Superior secondary endpoints: Significant reductions in joint bleeds, spontaneous bleeds, and target joint bleeding—all critical for long-term musculoskeletal health
Treatment Advantages:
- Fixed weekly SC dosing—no more reactive bypassing agent consumption
- Dramatic reduction in bypassing agent use: ~94% reduction in yearly aPCC and rFVIIa consumption
- Improved quality of life markers: Significant improvements in Haem-A-QoL physical health domain (−25.9 points, p<0.0001) and total score (−13.5 points, p<0.001
Safety Profile:
✔ Well-tolerated across both observational and active treatment phases
✔ No thromboembolic events detected in patients with inhibitors—a critical reassurance for TFPI targeting strategies
✔ Most adverse events mild to moderate; injection site reactions manageable
✔ ADA formation in 10/51 patients (19.6%) had no clinical impact—titers low with natural resolution”
All from ASH25 featured in Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers